Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Chief Technology Officer | March 14, 2017 | March 16, 2017 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | SVP, Chief Development Officer | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date March 14, 2017 · Filed March 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2027-03-14 | Direct | 75,000 |
Reported balance
After 2017-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-14 · Grant · Acquired 75,000 · Balance 75,000 F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.
SELLAS Life Sciences Group, Inc.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 557,805 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 300,000 · Balance 557,805 F1: The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 21:35 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002506 · tm262627-4_4seq1.xml · nonDerivative · entry 1 CICIC DRAGAN · CIK 0001565795 · SVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,805 F1 · shares: The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:07 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 63,800 | $1.50 | $95,700.00 |
DisclosureSEC source: 0001104659-25-118882 · tm2532693-3_4seq1.xml · nonDerivative · entry 1 CICIC DRAGAN · CIK 0001565795 · SVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,805 F1 · kind: Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 169,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001104659-25-003494 · tm253166-1_4seq1.xml · derivative · entry 3 CICIC DRAGAN · CIK 0001565795 · SVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,500 Underlying: Common Stock · 169,500 shares Expires 2035-01-10 F3 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 81,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003494 · tm253166-1_4seq1.xml · nonDerivative · entry 2 CICIC DRAGAN · CIK 0001565795 · SVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,628 F2 · shares: The Reporting Person received an award of 81,300 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003494 · tm253166-1_4seq1.xml · nonDerivative · entry 1 CICIC DRAGAN · CIK 0001565795 · SVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,328 F1 · shares: The Reporting Person received an award of 113,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 22:06 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 8,256 | $1.13 | $9,329.28 |
DisclosureSEC source: 0001104659-24-125944 · tm2430303-3_4seq1.xml · nonDerivative · entry 1 CICIC DRAGAN · CIK 0001565795 · SVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,328 F1 · kind: Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:07 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002450 · f4031417cicic_actinium.xml · derivative · entry 1 CICIC DRAGAN · CIK 0001565795 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.